Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Genzyme provides update on U.S. LEMTRADA™ filing
Extension CombiRx data show no benefit of combined MS drugs
Mitoxantrone-related acute leukemia in MS: An open or closed book?
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
Visualizing Non-Gaussian Diffusion: Clinical Application of q-Space Imaging and Diffusional Kurtosis Imaging of the Brain and Spine.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Klotho Is a Neuroprotective and Cognition-Enhancing Protein.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.
Gene expression analysis reveals functional pathways of glatiramer acetate activation.
Chemotherapeutics in the treatment of multiple sclerosis.
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...
Limit cycle oscillations in standing human posture.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)
Antioxidant properties of the triaminopyridine, flupirtine.

Pages